Skip to main content
Arctic Bioscience logo

Arctic Bioscience — Investor Relations & Filings

Ticker · ABS ISIN · NO0010859580 LEI · 549300Z2HW6I989Q2C78 OL Manufacturing
Open in API
Filings indexed 422 across all filing types
Latest filing 2025-02-20 Report Publication Anno…
Country NO Norway
Listing OL ABS

About Arctic Bioscience

https://arctic-bioscience.com/

Arctic Bioscience is a biotechnology company that develops and commercializes pharmaceutical and nutraceutical products derived from marine membrane lipids. The company utilizes proprietary technology to extract bioactive compounds from herring roe, sourced from sustainable, MSC-certified fisheries. Its nutraceutical product line, marketed under the brand name Romega, consists of high-DHA Omega-3 phospholipid extracts. The pharmaceutical division is focused on developing a novel drug candidate for the treatment of mild-to-moderate psoriasis, aligning with its mission to create therapies for autoimmune disorders. The company's work is supported by extensive research and development to validate the efficacy of its marine-based ingredients.

Recent filings

Filing Released Lang Actions
Arctic Bioscience - Invitation to presentation of Q4 2024 operational update
Report Publication Announcement Classification · 98% confidence The document is an invitation announcing that Arctic Bioscience will publish its Q4 2024 operational update on February 27th and will host a webcast/Q&A session on the same day to present the results. Since the document's primary function is to announce the upcoming publication of results and the associated presentation/call, it fits the definition of a Report Publication Announcement (RPA). It is not the full earnings release (ER) or the call transcript (CT) itself, but the notice about them. The document length is short (1926 chars), supporting the RPA classification based on the 'MENU VS MEAL' rule.
2025-02-20 English
Arctic Bioscience - Invitasjon til presentasjon av operasjonell oppdatering for 4. kvartal 2024
Report Publication Announcement Classification · 95% confidence The document is an invitation announcing that Arctic Bioscience will release an 'operasjonell oppdatering' (operational update) for Q4 2024 on February 27th, followed by a webcast presentation with Q&A. This is not the actual report (like an IR or ER), but an announcement about the upcoming release and presentation of results/updates. Since it announces a presentation/call where results will be discussed, it strongly relates to an Earnings Release (ER) or Call Transcript (CT). However, the primary purpose of this short document is to announce the *event* (webcast/presentation) where the operational update will be shared. Given the context of announcing a specific event for presenting results and operational status, it functions as a precursor to an Earnings Release or a Call Transcript announcement. Because it explicitly invites participation in a webcast/Q&A session following the release of the operational update, it is most closely aligned with the context of an Earnings Release (ER) announcement, even though it's not the full release itself. However, applying Rule #2 (Menu vs Meal), since this is a short announcement about an upcoming event where results will be presented, it fits the description of an announcement rather than the full report. If the content were the transcript, it would be CT. If it were the full financial highlights, it would be ER. Since it is an invitation to the presentation event itself, and it is very short, it is best classified as a Report Publication Announcement (RPA) because it announces the publication/presentation of the operational update, or potentially RNS as a general announcement. Given the specific nature of announcing a results presentation, RPA is a strong fit, as it announces the publication of the operational update and the associated presentation event. I will choose RPA as it announces the publication/event related to the operational update.
2025-02-20 Norwegian
Arctic Bioscience - Share capital increase registered
Share Issue/Capital Change Classification · 98% confidence The document explicitly announces that a 'Share capital increase registered' following a previous approval related to the 'issuance of new shares'. It details the change in the total share capital amount and the number of shares. This directly relates to changes in the company's capital structure, specifically through the issuance of new shares. This aligns perfectly with the definition for 'Share Issue/Capital Change' (Code: SHA). The document is short and is an announcement of a corporate action, not a comprehensive report.
2025-02-10 English
Arctic Bioscience - Registrert aksjekapitalforhøyelse
Share Issue/Capital Change Classification · 98% confidence The document is a short announcement titled "Arctic Bioscience - Registrert aksjekapitalforhøyelse" (Registered Share Capital Increase). It explicitly states that the increase in share capital has been registered in the Register of Business Enterprises and provides the new total share capital and number of shares. This directly relates to a change in the company's capital structure due to the issuance of new shares following debt conversion. This aligns perfectly with the definition for Capital/Financing Update (CAP). It is not a full report (10-K, IR), an earnings release (ER), or a dividend notice (DIV). Given the specific nature of the capital change announcement, CAP is the most appropriate classification over the general RNS.
2025-02-10 Norwegian
Arctic Bioscience - Board approval of share capital increase related to conversion of debt
Capital/Financing Update Classification · 98% confidence The document is titled 'REDEGJØRELSE I ANLEDNING KAPITALFORHØYELSE' (Statement Regarding Capital Increase) and details the process of increasing share capital by issuing new shares in exchange for offsetting existing debt (convertible loans). It explicitly references Norwegian company law requirements (§10-17, §10-2, §2-6) for such transactions, which typically require a formal statement from the board and an auditor's confirmation regarding the value of the non-cash contribution (the debt offset). The presence of a formal auditor's statement ('Uttalelse om redegjørelse ved oppgjør av aksjeinnskudd ved motregning' from PricewaterhouseCoopers AS) confirming compliance with the requirements for non-cash contributions strongly suggests this is a regulatory filing related to capital structure changes, rather than a general annual report (10-K) or a simple earnings release (ER). Reviewing the definitions: - 10-K: No, this is too specific and short for a full annual report. - ER: No, this is about capital structure, not operating results. - AR: No, this is not a general audit report. - CAP (Capital/Financing Update): This fits well as it details a capital increase and financing structure change. - SHA (Share Issue/Capital Change): This is also highly relevant as it is a direct capital change. Since the document is a formal, legally mandated statement detailing the mechanics and valuation of a capital increase via debt conversion, it falls under the scope of financing activities and capital structure changes. 'Capital/Financing Update' (CAP) is the most precise fit for a formal statement detailing the issuance of new shares against debt conversion, which is a financing event. While 'SHA' is related, 'CAP' often covers the formal documentation surrounding such complex financing maneuvers involving debt conversion. Given the focus on the legal requirements for non-cash contributions to capital, 'CAP' is selected as the primary classification.
2025-02-03 Norwegian
Arctic Bioscience - Styrets godkjennelse av kapitaløkning relatert til gjeldskonvertering
Capital/Financing Update Classification · 98% confidence The document is titled 'REDEGJØRELSE I ANLEDNING KAPITALFORHØYELSE' (Statement Regarding Capital Increase) and details the process of increasing share capital by issuing new shares in exchange for offsetting existing debt (convertible loans). It explicitly references Norwegian company law requirements (§10-17, §10-2, §2-6) for such transactions, which typically require a formal statement from the board and an auditor's confirmation regarding the value of the non-cash contribution (the debt offset). The presence of a formal auditor's statement ('Uttalelse om redegjørelse ved oppgjør av aksjeinnskudd ved motregning' from PricewaterhouseCoopers AS) confirming compliance with the requirements for non-cash contributions strongly suggests this is a regulatory filing related to capital structure changes, rather than a general annual report (10-K) or a simple earnings release (ER). Reviewing the definitions: - 10-K: No, this is too specific and short for a full annual report. - ER: No, this is about capital structure, not operating results. - AR: No, this is not a general audit report. - CAP (Capital/Financing Update): This fits well as it details a capital increase and financing structure change. - SHA (Share Issue/Capital Change): This is also highly relevant as it is a direct capital change. Since the document is a formal, legally mandated statement detailing the mechanics and valuation of a capital increase via debt conversion, it falls under the scope of financing activities and capital structure changes. 'Capital/Financing Update' (CAP) is the most precise fit for a formal statement detailing the issuance of new shares against debt conversion, which is a financing event. While 'SHA' is related, 'CAP' often covers the formal documentation surrounding such complex financing maneuvers involving debt conversion. Given the focus on the legal requirements for non-cash contributions to capital, 'CAP' is selected as the primary classification.
2025-02-03 Norwegian

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.